Antibiotic consumption and generation of resistance in Streptococcus pneumoniae: The paradoxical impact of quinolones in a complex selective landscape

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 3, 2006, Pages 55-66

  García Rey, Cesar ^a   Martin Herrero J E ^a   Baquero, F ^b  

^a GLAXOSMITHKLINE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antibiotic consumption; Pneumoniae; Quinolones; Resistance; Review; Streptococcus

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PENICILLIN G; PIPEMIDIC ACID; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CORRELATION ANALYSIS; DISEASE SURVEILLANCE; DRUG HALF LIFE; DRUG SELECTIVITY; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; GEOGRAPHY; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LINEAR REGRESSION ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; PENICILLIN RESISTANCE; PREVALENCE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SEROTYPE; SPAIN; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; SALIX; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 33645799969     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01397.x     Document Type: Review

References (71)

1. Murray JF. A thousand years of pulmonary medicine: Good news and bad. Eur Respir J 2001; 17: 558-65.
2. Bronzwaer SL, Cars O, Buchholz U et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8: 278-82.
3. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005: 365, 579-87.
4. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851-3.
5. Garcia-Rey C, Fenoll A, Aguilar L, Casal J. Effect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in Spain. J Antimicrob Chemother 2004; 54: 465-71.
6. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Dal-Re R. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 2002; 40: 159-64.
7. Lazaro Bengoa E, Madurga Sanz M, Abajo Iglesias FJ. Trends in antibiotic consumption in Spain, 1985-2000. Med Clin (Barc) 2002; 118: 561-8.
8. Bremon AR, Ruiz-Tovar M, Gorricho BP, de Torres PD, Rodriguez RL. Non-hospital consumption of antibiotics in Spain 1987-97. J Antimicrob Chemother 2000; 45: 395-400
9. Ronning M, Blix HS, Strom H, Skovlund E, Andersen M, Stichele RV. Problems in collecting comparable national drug use data in Europe. the example of antibacterials. Eur J Clin Pharmacol 2003; 58: 843-9.
10. Ruiz Bremon A, Ruiz Tovar M. Antimicrobial consumption. Information sources and unity of measures. Rev Esp Quimioter 2003; 16: 132-4.
11. Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337: 441-6.
12. Seppala H, Klaukka T, Lehtonen R, Nenonen E, Huovinen P. Outpatient use of erythromycin: Link to increased erythromycin resistance in group A streptococci. Clin Infect Dis 1995; 21: 1378-85.
13. Kristinsson KG. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb Drug Resist 1997; 3: 117-23.
14. Chen DK, McGeer A, de Azavedo JC. Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-9.
15. Baquero F, Martinez-Beltran J, Loza E. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. J Antimicrob Chemother 1991; 28 (Suppl. C): 31-8.
16. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999; 96: 1152-6.
17. Lipsitch M, Levin BR. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997; 41: 363-73.
18. Levin BR, Lipsitch M, Perrot V et al. The population genetics of antibiotic resistance. Clin Infect Dis 1997; 24 (Suppl. 1): S9- 6.
19. Negri MC, Morosini MI, Loza E, Baquero F. In vitro selective antibiotic concentrations of beta-lactams for penicillin-resistant Streptococcus pneumoniae populations. Antimicrob Agents Chemother 1994; 38: 122-5.
20. Melander E, Ekdahl K, Jonsson G, Molstad S. Frequency of penicillin-resistant pneumococci in children is correlated to community utilization of antibiotics. Pediatr Infect Dis J 2000; 19: 1172-7.
21. Cizman M, Pokorn M, Seme K, Paragi M, Orazem A. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens. Eur J Clin Microbiol Infect Dis 1999; 18: 522-4.
22. Cizman M, Pokorn M, Seme K, Orazem A, Paragi M. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J Antimicrob Chemother 2001; 47: 475-7.
23. Cizman M, Orazem A, Krizan-Hergouth V, Kolman J. Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections. J Antimicrob Chemother 2001; 47: 502.
24. de Neeling AJ, Overbeek BP, Horrevorts AM, Ligtvoet EE, Goettsch WG. Antibiotic use and resistance of Streptococcus pneumoniae in The Netherlands during the period. J Antimicrob Chemother 2001 1994-99; 48: 441-4.
25. Reinert RR, Al-Lahham A, Lemperle M et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002; 49: 61-8.
26. McCormick AW, Whitney CG, Farley MM et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003; 9: 424-30.
27. Baquero F. Antibiotic resistance in Spain. what can be done? Task Force of the General Direction for Health Planning of the Spanish Ministry of Health. Clin Infect Dis 1996; 23: 819-23.
28. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: A link with long-acting macrolide consumption? J Chemother 1999; 11 (Suppl. 1): 35-43.
29. Baquero F, Baquero-Artigao G, Canton R, Garcia-Rey C. Antibiotic consumption and resistance selection in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 50 (Suppl. 2): 27-37.
30. Khan AQ, Chen Q, Wu ZQ, Paton JC, Snapper CM. Both innate immunity and type 1 humoral immunity to Streptococcus pneumoniae are mediated by MyD88 but differ in their relative levels of dependence on toll-like receptor 2. Infect Immun 2005; 73: 298-307.
31. Kadioglu A, Andrew PW. The innate immune response to pneumococcal lung infection: The untold story. Trends Immunol 2004; 25: 143-9.
32. Opitz B, Puschel A, Schmeck B et al. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 2004; 279: 36426-32.
33. Baquero F, Garcia-Rodriguez JA, de Lomas JG, Aguilar L. Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: Results of a 1-year (1996-97) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 1999; 43: 178-80.
34. Baquero F, Garcia-Rodriguez JA, Garcia de Lomas J, Aguilar L. Antimicrobial resistance of 1113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-97) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 1999; 43: 357-9.
35. Garcia-Rodriguez JA, Baquero F, Garcia de Lomas J, Aguilar L. Antimicrobial susceptibility of 1422 Haemophilus influenzae isolates from respiratory tract infections in Spain. Results of a 1-year (1996-97) multicenter surveillance study. Spanish Surveillance Group for Respiratory Pathogens. Infection 1999; 27: 265-7.
36. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: Results of a 1-year (1998-99) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45: 3334-40.
37. Marco F, Garcia-de-Lomas J, Garcia-Rey C, Bouza E, Aguilar L, Fernandez-Mazarrasa C. Antimicrobial susceptibilities of 1730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-99. Antimicrob Agents Chemother 2001; 45: 3226-8.
38. Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-72.
39. Alou L, Ramirez M, Garcia-Rey C, Prieto J, de Lencastre H. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain. clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrob Agents Chemother 2001; 45: 2955-7.
40. Alberti S, Cortes G, Garcia-Rey C et al. Streptococcus pyogenes pharyngeal isolates with reduced susceptibility to ciprofloxacin in Spain: Mechanisms of resistance and clonal diversity. Antimicrob Agents Chemother 2005; 49: 418-20.
41. Alberti S, Garcia-Rey C, Dominguez MA et al. Survey of emm gene sequences from pharyngeal Streptococcus pyogenes isolates collected in Spain and their relationship with erythromycin susceptibility. J Clin Microbiol 2003; 41: 2385-90.
42. Alberti S, Garcia-Rey C, Garcia-Laorden MI, Dal-Re R, Garcia-de-Lomas J. Survey of emm -like gene sequences from pharyngeal isolates of group C and group G streptococci collected in Spain. J Clin Microbiol 2005; 43: 1433-6.
43. Perez-Trallero E, Marimon JM, Gonzalez A, Garcia-Rey C, Aguilar L. Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother 2003; 47: 3637-9.
44. Granizo JJ, Aguilar L, Casal J, Garcia-Rey C, Dal-Re R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-97). J Antimicrob Chemother 2000; 46: 767-73.
45. Granizo JJ, Aguilar L, Casal J, Dal-Re R, Baquero F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain. J Antimicrob Chemother 2000 1986-97; 46: 959-64.
46. Young FW, Rodriguez E. Types of provincial structure and population health. Soc Sci Med 2005; 60: 87-95
47. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Martin JE. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J Clin Microbiol 2002; 40: 2959-63.
48. Monnet DL, Lopez-Lozano JM. Relationship between antibiotic consumption and resistance in European hospitals. Med Mal Infect 2005; 35 (Suppl. 2): S127-8.
49. Lopez-Lozano JM, Monnet DL, Yague A et al. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: A time series analysis. Int J Antimicrob Agents 2000; 14: 21-31.
50. Monnet DL, Lopez-Lozano JM, Campillos P, Burgos A, Yague A, Gonzalo N. Making sense of antimicrobial use and resistance surveillance data. application of ARIMA and transfer function models. Clin Microbiol Infect 2001; 7 (Suppl. 5): 29-36.
51. Muller AA, Mauny F, Bertin M et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French University hospital. Clin Infect Dis 2003; 36: 971-8
52. Muller A, Lopez-Lozano JM, Bertrand X, Talon D. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother 2004; 54: 173-7.
53. Monnet DL, MacKenzie FM, Lopez-Lozano JM et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004; 10: 1432-41.
54. Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J. Trends in antimicrobial resistance in 1,968 invasive Streptococcus pneumoniae strains isolated in Spanish hospitals (2001-03): Decreasing penicillin resistance in children's isolates. J Clin Microbiol 2004; 42: 5571-7.
55. Oteo J, Campos J, Cruchaga S et al. Increase of resistance to macrolides in invasive Streptococcus pneumoniae in Spain (2000-01). Clin Microbiol Infect 2004; 10: 851-4.
56. Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J. Antimicrobial-resistant invasive Escherichia coli. Spain Emerg Infect Dis 2005; 11: 546-53.
57. Andreu A, Alos JI, Gobernado M, Marco F, de la Rosa M, Garcia-Rodriguez JA. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: A nationwide surveillance study. Enferm Infecc Microbiol Clin, 2005; 23: 4-9.
58. Latorre C, Garcia-Rey C, Garcia-Perea A et al. Activity of six quinolones against 226 recent clinical isolates of Streptococcus pyogenes with reduced susceptibility to ciprofloxacin. J Antimicrob Chemother, 2002; 50: 301-3.
59. Anatomical Therapeutic Chemical (ATC) classification index with Defined Daily Doses (DDDs). Norway: WHO Collaborating Centre for Drug Statistics Methodology, 2002.
60. Monnet DL. ABC Calc - Antibiotic consumption calculator [Microsoft Excel application], Version 1.8. Copenhagen (Denmark): Staten Serum Institut, 2002.
61. Ruiz Tovar M, Ruiz Bremon A. Consumo de quinolonas en el medio extrahospitalario en España. Boletín Epidemiológico Semanal. Instituto Salud Carlos III. Ministerio Sanidad y Consumo 1998; 6: 265-7.
62. Zhanel GG, Roberts D, Waltky A et al. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother, 2002; 49: 807-12.
63. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483-90.
64. Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-7.
65. Giraud E, Cloeckaert A, Baucheron S, Mouline C, Chaslus-Dancla E. Fitness cost of fluoroquinolone resistance in Salmonella enterica serovar Typhimurium. J Med Microbiol 2003; 52: 697-703.
66. Kugelberg E, Lofmark S, Wretlind B, Andersson DI. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J Antimicrob Chemother, 2005; 55: 22-30.
67. Komp Lindgren P, Marcusson LL, Sandvang D, Frimodt-Moller N, Hughes D. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother 2005; 49: 2343-51.
68. Baquero F. Trends in antibiotic resistance of respiratory pathogens: An analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother, 1996; 38 (Suppl. A): 117-32.
69. Arason VA, Gunnlaugsson A, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG. Clonal spread of resistant pneumococci despite diminished antimicrobial use. Microb Drug Resist 2002; 8: 187-92.
70. Garcia-Rey C, Aquilar L, Baquero F. Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain. Antimicrob Agents Chemother 2000; 44: 3481-2.
71. Perez-Trallero E, Marimon JM, Gonzalez A, Vicente D, Garcia-Arenzana JM. Spectrum of antibiotic resistance of the Spain14-5 Streptococcus pneumoniae clone over a 22 year period. J Antimicrob Chemother 2004; 53: 620-5.